cox 189 has been researched along with trinitrobenzenesulfonic acid in 2 studies
| Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (trinitrobenzenesulfonic acid) | Trials (trinitrobenzenesulfonic acid) | Recent Studies (post-2010) (trinitrobenzenesulfonic acid) |
|---|---|---|---|---|---|
| 163 | 49 | 47 | 2,710 | 10 | 1,042 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Oliveira Costa, H; Franco, M; Miszputen, SJ; Oshima, CT; Paiotti, AP; Ribeiro, DA | 1 |
| Franco, M; Marchi, P; Miszputen, SJ; Neto, RA; Oshima, CT; Paiotti, AP; Ribeiro, DA; Silva, RM | 1 |
2 other study(ies) available for cox 189 and trinitrobenzenesulfonic acid
| Article | Year |
|---|---|
Effect of COX-2 inhibitor after TNBS-induced colitis in Wistar rats.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Inflammatory Bowel Diseases; Rats; Rats, Wistar; RNA, Messenger; Trinitrobenzenesulfonic Acid | 2009 |
Effect of COX-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in Wistar rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Inflammatory Bowel Diseases; Male; Random Allocation; Rats; Rats, Wistar; Receptors, Tumor Necrosis Factor; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2012 |